v3.25.3
Segment Reporting (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2025
USD ($)
segment
operatingSegment
Sep. 30, 2024
USD ($)
Segment Reporting [Abstract]        
Number of operating segment | operatingSegment     1  
Number of reportable segment | segment     1  
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Product revenues, net $ 142,342 $ 93,425 $ 342,580 $ 259,265
Cost of product revenues (excluding amortization of intangible assets) 29,365 21,170 78,718 59,591
Research and development 186,415 150,809 516,182 418,640
Amortization of intangible assets 1,538 1,263 4,064 3,789
Change in fair value of deferred and contingent consideration liabilities 104,653 14,682 181,953 106,482
Investment income (18,289) (16,982) (45,420) (36,050)
Interest expense 20,382 21,054 63,196 63,363
Provision for income taxes 1,320 1,014 3,475 2,441
Net loss (370,021) (220,524) (948,290) (678,224)
ARIKAYCE external R&D expenses        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Product revenues, net 114,291 93,425 314,529 259,265
Reportable Segment        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Product revenues, net 142,342 93,425 342,580 259,265
Cost of product revenues (excluding amortization of intangible assets) 29,365 21,170 78,718 59,591
R&D compensation and benefit-related expenses 63,817 50,778 173,764 136,146
SG&A compensation and benefit-related expenses 62,287 47,578 168,443 115,250
Other segment items 150,930 94,721 398,275 261,889
Depreciation 2,458 1,459 6,825 4,483
Amortization of intangible assets 1,538 1,263 4,064 3,789
Change in fair value of deferred and contingent consideration liabilities 104,653 14,682 181,953 106,482
Investment income (18,289) (16,982) (45,420) (36,050)
Interest expense 20,382 21,054 63,196 63,363
Provision for income taxes 1,320 1,014 3,475 2,441
Net loss (370,021) (220,524) (948,290) (678,224)
Reportable Segment | ARIKAYCE external R&D expenses        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Research and development 9,214 16,370 32,338 45,192
Reportable Segment | Brensocatib external R&D expenses        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Research and development 19,355 17,288 73,576 74,612
Reportable Segment | TPIP external R&D expenses        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Research and development 28,754 16,635 58,556 45,190
Reportable Segment | Other external R&D expenses        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Research and development $ 36,579 $ 26,919 $ 93,107 $ 55,111